Sotac Pharmaceuticals Complete Financial Statements
In FY2024, Sotac Pharmaceuticals (SOTAC) reported revenue ₹28 Cr, net profit ₹1 Cr and EPS ₹0.42, with a net profit margin of 3.6% and ROE of 1.7%. Full financial statements from FY2020 to FY2026 (7 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
SOTAC Revenue, Net Profit & EBITDA — Year-on-Year Growth
SOTAC YoY (Sept 2023 vs Sept 2024) — revenue +3.7%, EBITDA +50.0%. For live price, earnings ratios and company overview, see Sotac Pharmaceuticals share price screener.
SOTAC Income Statement — Revenue, EBITDA & Net Profit
Sotac Pharmaceuticals revenue ₹28 Cr, EBITDA ₹3 Cr, net profit ₹1 Cr, EPS ₹0.42 (2024) — net profit margin 3.6%. Compare with SOTAC stock valuation models to assess whether the stock is under or overvalued.
| Particulars | Sept 2024 | Mar 2024 | Jun 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28 | 27 | 26 | 27 | 18 | 25 | 26 | 41 | 20 |
| Expenses | 25 | 25 | 23 | 25 | 16 | 23 | 23 | 36 | 18 |
| EBITDA | 3 | 2 | 3 | 2 | 3 | 3 | 3 | 4 | 2 |
| Operating Profit Margin % | 8.00% | 4.00% | 9.00% | 8.00% | 13.00% | 9.00% | 10.00% | 9.00% | 9.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Profit Before Tax | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 1 |
| Tax | 1 | -1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Net Profit | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Earnings Per Share (₹) | 0.42 | 1.49 | 1.32 | 0.58 | 1.58 | 1.01 | 0.82 | 4.41 | 0.29 |
SOTAC Balance Sheet — Assets, Liabilities & Shareholders' Equity
SOTAC total assets ₹134 Cr, total equity ₹59 Cr, total liabilities ₹ Cr (2026) — ROE 1.7%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Total Assets | 134 | 124 | 105 | 74 | 35 | 30 |
| Current Assets | 78 | 70 | 61 | 47 | 17 | 14 |
| Fixed Assets | 50 | 49 | 36 | 26 | 17 | 16 |
| Capital Work in Progress | 2 | 0 | 5 | 0 | 0 | 0 |
| Investments | 27 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 75 | 65 | 48 | 18 | 14 |
| LIABILITIES | ||||||
| Total Liabilities | ||||||
| Current Liabilities | 11 | 14 | 12 | 8 | 9 | 6 |
| Non-Current Liabilities | ||||||
| SHAREHOLDERS' EQUITY | ||||||
| Total Equity | 59 | 58 | 49 | 20 | 3 | 5 |
| Share Capital | 11 | 11 | 11 | 8 | 2 | 2 |
| Reserves & Surplus | 48 | 42 | 34 | 2 | 0 | 1 |
SOTAC Cash Flow Statement — Operating, Investing & Financing
Sotac Pharmaceuticals operating cash flow ₹-4 Cr, investing ₹-14 Cr, financing ₹16 Cr, net cash flow ₹-2 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2021 | March 2020 |
|---|---|---|---|---|---|
| Operating Activities | -4 | -16 | 8 | 0 | 0 |
| Investing Activities | -14 | -20 | -12 | -3 | -12 |
| Financing Activities | 16 | 30 | 13 | 3 | 11 |
| Net Cash Flow | -2 | -6 | 10 | 0 | 0 |